. Author manuscript; available in PMC: 2023 Jan 1.

Published in final edited form as: Am J Ophthalmol. 2021 Jul 21;233:189–215. doi: 10.1016/j.ajo.2021.07.016

Table 10.

Characteristics of Eyes Receiving Anti-VEGF Versus Laser

Primary Treatment	Laser (n=190)	IVB (n=60)	p-value

Mean Birthweight (grams, std dev)	679 ± 169.3	593.4 ± 114.7	p = 0.0003^*
Mean Gestational Age (weeks, std dev)	24.9 ± 1.6	24.4 ± 1.1	p = 0.031^*
Mean Adjusted Age of Treatment (weeks, std dev)	37.7 ± 3.25	35.9 ± 2.28	p < 0.001^*
Micropremature Infants (<750g BW)	128 (67.4%)	56 (93.3%)	p = 0.001^#
Progression to Stage 4 or 5 Disease	3.4%	0.0%

T-test comparison of mean average of ROP infants who received treatment versus non-treated

Chi-square comparison of ROP infants who received treatment versus non-treated

Abbreviations: BW - birthweight, g - grams, IVB - intravitreal bevacizumab, n - number, std dev - standard deviation, VEGF - vascular endothelial growth factor